135 related articles for article (PubMed ID: 23290145)
1. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma.
Darwish OM; Kapur P; Youssef RF; Bagrodia A; Belsante M; Alhalabi F; Sagalowsky AI; Lotan Y; Margulis V
Urology; 2013 Mar; 81(3):581-6. PubMed ID: 23290145
[TBL] [Abstract][Full Text] [Related]
2. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.
Haddad AQ; Kapur P; Singla N; Raman JD; Then MT; Nuhn P; Buchner A; Bastian P; Seitz C; Shariat SF; Bensalah K; Rioux-Leclercq N; Sagalowsky A; Lotan Y; Margulis V
Cancer; 2015 Jan; 121(1):43-50. PubMed ID: 25186283
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.
Bagrodia A; Krabbe LM; Gayed BA; Kapur P; Bernstein I; Xie XJ; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclerq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Margulis V
Urology; 2014 Nov; 84(5):1134-40. PubMed ID: 25443916
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma.
Gayed BA; Youssef RF; Bagrodia A; Kapur P; Darwish OM; Krabbe LM; Sagalowsky A; Lotan Y; Margulis V
J Urol; 2013 Nov; 190(5):1662-7. PubMed ID: 23792148
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
6. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
7. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.
Chaux A; Albadine R; Schultz L; Hicks J; Carducci MA; Argani P; Allaf M; Netto GJ
Hum Pathol; 2013 Oct; 44(10):2323-30. PubMed ID: 23953228
[TBL] [Abstract][Full Text] [Related]
9. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
10. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer.
Dahinden C; Ingold B; Wild P; Boysen G; Luu VD; Montani M; Kristiansen G; Sulser T; Bühlmann P; Moch H; Schraml P
Clin Cancer Res; 2010 Jan; 16(1):88-98. PubMed ID: 20028743
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.
Belsante M; Darwish O; Youssef R; Bagrodia A; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
Urol Oncol; 2014 Jan; 32(1):30.e23-8. PubMed ID: 23428539
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of β-catenin is an independent predictor of oncologic outcomes in patients with clear cell renal cell carcinoma.
Krabbe LM; Westerman ME; Bagrodia A; Gayed BA; Darwish OM; Haddad AQ; Khalil D; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
J Urol; 2014 Jun; 191(6):1671-7. PubMed ID: 24291548
[TBL] [Abstract][Full Text] [Related]
14. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
[TBL] [Abstract][Full Text] [Related]
16. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma.
Gayed BA; Youssef RF; Bagrodia A; Darwish OM; Kapur P; Sagalowsky A; Lotan Y; Margulis V
BJU Int; 2014 Apr; 113(4):668-73. PubMed ID: 23937277
[TBL] [Abstract][Full Text] [Related]
17. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
[TBL] [Abstract][Full Text] [Related]
18. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
[TBL] [Abstract][Full Text] [Related]
19. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era.
Clark PE; Veys JA; Eskridge MR; Woodruff RD; Hall MC
Urol Oncol; 2005; 23(5):328-32. PubMed ID: 16144666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
